Safety and Clinical Responses in Ankylosing Spondylitis after Three Months of Etanercept Therapy by Choi, Chan-Bum et al.
INTRODUCTION
Ankylosing spondylitis (AS) is a chronic, progressive,
inflammatory disorder of unknown etiology that affects up
to 1% of the population worldwide (1). It usually starts in
sacroiliac joints with axial skeleton involvement as the dis-
ease progresses with inflammation of the joints and entheses
eventually leading to new bone formation with syndesmo-
phytes and ankylosis. Also, peripheral joint may be involved.
It usually begins in late teens in Korea (2) and imposes con-
siderable disease burden with disability and deformity (3).
Nonsteroidal antiinflammatory drugs (NSAIDs) had been
proven effective in AS (4), but unfortunately its efficacy is
often unsatisfactory and a considerable number of patients
are unable to maintain NSAIDs due to adverse events such as
gastrointestinal disturbance or its effect on the cardiovascular
system. Disease-modifying antirheumatic drugs (DMARDs)
such as sulfasalazine may be effective in peripheral arthritis,
but there is no evidence that DMARDs are effective in axial
involvement (5). Short-term effects of physical therapy in
AS have been validated (6), but evidence for long-term effec-
tiveness is lacking. 
There have been numerous reports of tumor necrosis fac-
tor (TNF) playing an important role in AS. Mice transplant-
ed with TNF-αexpressing gene presenting joint symptoms
similar to that of AS (7), and increase in serum TNF-αlevel
in AS patients compared to other noninflammatory back
pain patients have been reported (8). Increased expression of
TNF-αmRNA and TNF protein in the sacroiliac joints
demonstrated that TNF-αplays an important role in patho-
genesis of AS and it was suggested that TNF blocker would
be effective in treating AS (9). 
Introduction of agents targeted against TNF, a proinflam-
matory cytokine, has provided an effective modality in treat-
ing AS. Both etanercept, a dimeric fusion protein of the TNF
receptor and the Fc portion of IgG1, and infliximab, a mon-
oclonal antibody that targets TNF, were significantly effec-
tive in improving pain and function in AS in randomized
clinical trials (10-12). Adverse events related to TNF inhibitors
includes injection site reactions, increased risk of infection-
especially tuberculosis (TB), development of antinuclear
antibodies, lupus-like syndrome, demyelinating diseases,
and worsening of preexisting congestive heart failure. Among
these adverse events, injection site reaction is relatively com-
mon, especially with etanercept, but it usually diminished
with repeated injections and does not pose a serious threat
and incidence of TB have decreased with implementation
of meticulous screening for TB and standardized guideline
for treatment of latent TB in patients treated with TNF
inhibitors. 
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Safety and Clinical Responses in Ankylosing Spondylitis after Three
Months of Etanercept Therapy
We aimed to evaluate the safety and clinical responses in Korean ankylosing spondyli-
tis (AS) patients after three months of etanercept therapy. AS patients satisfying
the Modified New York Criteria were enrolled. They were assessed for safety and
clinical responses at enrollment and after three months of etanercept therapy. A
total of 124 patients completed the study. After three months, the rate of ASsess-
ment in AS International Working Group 20% improvement (ASAS 20) response
was 79.8%. The rates of ASAS 40 and ASAS 5/6 responses were 58.5 and 62.8%,
respectively. Significant improvement of Korean version of Bath AS Disease Activ-
ity Index (KBASDAI) (p<0.0001), Bath AS Functional Activity Index (BASFI) (p<
0.0001), and Bath AS Metrology Index (BASMI) (p=0.0009) were achieved after
three months. Quality of life was also significantly improved after three months, as
demonstrated by scores for SF-36 (p<0.0001) and EQ-5D (p<0.0001). Erythro-
cyte sedimentation rate and C-reactive protein were significantly decreased (p<
0.0001, p<0.0001, respectively). None of the patients developed tuberculosis and
there were no serious adverse event. AS patients with inadequate response to
conventional therapy showed significant clinical improvement without serious adverse
events after three months of etanercept therapy.
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In this work, we report results of clinical effectiveness mea-
sured by improvement in disease activity, function, metro-
logic measurements, acute phase reactants, and quality of life
in both mental and physical domains after three months of
etanercept therapy in Korean patients with AS.
MATERIALS AND METHODS
Subjects
A total of 132 AS patients fulfilling the modified New
York criteria for the diagnosis of AS (13) initiating etaner-
cept therapy due to lack of efficacy for NSAIDs and/or DM-
ARDs were recruited consecutively from May 12th, 2005
to March 31st, 2006 at the Hospital for Rheumatic Dis-
eases, Hanyang University. The patients included in the
study were required to have severe active disease with inap-
propriate response to at least three consecutive months of
treatment with NSAIDs and/or DMARDs as defined by a
Korean version of Bath AS Activity Index (KBASDAI) (14)
of over or equal to four and bilateral grade two or unilateral
grade three sacroilitis. Patients who had received a biologic
agent in the past were excluded.
All patients were screened for TB by detailed history, chest
radiograph, and purified protein derivate tuberculin skin
test (TST). Patients were required to have either negative
result for TB or had received at least three weeks of prophy-
lactic treatment for TB if tested positive for latent TB with
induration of 10 mm or greater on TST. Patients with history
of active TB, history of recent close contact with a known
TB patient, or evidence of TB on chest radiograph were
excluded. Patients with other rheumatologic diseases, chron-
ic infection, congestive heart failure, or malignancy were
also excluded. The study protocol was approved by institu-
tional review board of Hanyang University Hospital and all
patients provided written consent. 
Methods
Etanercept was administered subcutaneously at a fixed
dose of 25 mg twice a week for three months. DMARDs,
NSAIDs, and steroids were either continued or discontin-
ued according to the clinical judgment of the investigator. 
The patients were evaluated for disease activity using the
KBASDAI which assesses fatigue, spinal pain, joint pain,
joint swelling, areas of localized tenderness, and morning
stiffness, C-reactive protein (CRP), and erythrocyte sedimen-
tation rate (ESR). Functional limitation was evaluated using
Bath AS Functional Activity Index (BASFI), which assesses
activities related to functional anatomy, and the patient’s abil-
ity to cope with everyday life (15). Spinal movement was
evaluated using Bath AS Metrology Index (BASMI), which
measures cervical rotation, tragus to wall distance, lumbar
side flexion, modified Schober’s, and intermalleolar distance
(16). Short Form Health Survey-36 (SF-36) and EuroQol 5
Dimensions (EQ-5D) (17) were used to evaluate the quality
of life.
Primary endpoint was the percentage of ASsessment of
Ankylosing Spondylitis International Working Group 20%
response criteria (ASAS20) responders (18) after three months.
ASAS20 response is defined as at least a 20% and 10 mm
visual analog scale (VAS) improvement on a 0-100 scale in
at least three of four following domains without worsening
of 20% or greater or 10 mm or greater VAS on a 0-100 scale
in the remaining fourth domain: physical function measured
by BASFI, spinal pain measures on a 0-100 mm VAS, patient
global assessment in the last week measured on a 0-100 mm
VAS, and inflammation measured as the mean of intensity
and duration of morning stiffness on KBASDAI.
Secondary endpoints included ASAS40 response defined
as at least a 40% and 20 mm VAS improvement on a 0-100
scale in at least three of four domains described in ASAS20
without worsening of 40% or greater or 20 mm or greater
VAS on a 0-100 scale in the remaining fourth domain (18),
ASAS five out of six response defined as 20% improvement
in five out of six following domains without deterioration in
the sixth domain: pain, patient global assessment, function,
inflammation, spinal mobility, and CRP (19), ASAS partial
remission defined as an absolute score smaller than two in
all of four ASAS domains (18), and improvement in KBAS-
DAI, BASFI, BASMI, ESR, CRP, SF-36, and EQ-5D after
three months. Concomitant medications were also assessed.
Patients were assessed for adverse events at three months
by physical examination performed by the investigator, lab-
oratory tests including complete blood cell count, liver func-
tion test, renal function test, and chest radiograph. 
Statistical analysis
A paired t-test was used to compare the mean differences
between baseline and after three months, and a non-paramet-
ric test, Wilcoxon test, was used to compared CRP and ESR.
RESULTS
A total of 124 patients completed the three month assess-
ment and eight patients were lost to follow-up due to per-
sonal reasons. The mean age was 32.4 yr with a male predomi-
nance of 84.1% and the mean disease duration was 14.0 yr
and 90.2% of the patients were positive for HLA-B27. The
percentage of patients with history of uveitis was 38.6% and
52.3% had peripheral joint involvement (Table 1). Sixteen
patients (12.9%) had a history of completely treated pul-
monary TB with no active lesions on their chest radiography
and 41 patients (33.1%) were tested positive to the TST. All
patients have reported having been vaccinated with Bacillusof Calmette and Guerin. Those tested positive to TST with
an induration greater than 10 mm were diagnosed as latent
TB and prophylactic treatment for TB with isoniazid 300
mg once daily for nine months was initiated. They were ini-
tiated on etanercept therapy after three weeks of prophylaxis
therapy according to the Guideline for the Treatment of Latent
TB in Patients Receiving Biologic Agents set forth by the
Korean Center for Diseases Control (20). All patients had
significant AS diseases activity with KBASDAI score of at
least 4. Health-related quality of life was also substantially
lower than in the general population (21). SF-36 physical
and mental component summary scores were low with 28.8
±7.5 and 31.3±10.3, respectively, compared to 82.6±17.0
and 76.6±19.2, respectively, in the general Korean popu-
lation (21) (Table 2). EQ-5D scores were also lower with EQ-
5D profile score and VAS of 0.5±0.2 and 4.0±2.0, respec-
tively, compared to 0.9±0.1 and 75.1±15.3, respectively,
in the general Korean population (22) (Table 2). 
After three months, ASAS 20 was achieved in 99 of 124
patients (79.8%). ASAS 40, ASAS 5/6, and ASAS partial
remission were achieved in 73 (58.9%), 77 (62.1%), and 8
(6.5%) patients, respectively (Fig. 1). There were no signifi-
cant differences in ASAS response criteria according to dis-
ease duration.
Significant improvement in KBASDAI score was achieved
after three months (p<0.001) and BASFI and BASMI scores
also showed a significant improvement (p<0.001, for both com-
parisons) (Table 2). Only 14 (9.9%) patients failed to show a
KBASDAI score of less than four after three months. Signifi-
cant improvement was achieved in all domains of the KBA-
SDAI with the neck, back, and hip pain domain showing the
greatest improvement followed by the morning stiffness inten-
sity domain (Table 2). Improvements in BASMI domains
were less significant with the cervical rotation and intermalle-
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Characteristics n (%)
Age, mean±SD (yr) 32.4±8.3
Sex, M:F (male) 111:21 (84.1)
Disease duration, mean±SD (yr) 14.0±6.3
HLA-B27 positive 119 (90.2)
Peripheral joint involvement 69 (52.3)
History of uveitis 51 (38.6)
History of TB 16 (12.1)
Tuberculin test positive 41 (33.1)
Table 1. Baseline characteristics of the patients
Baseline After 3 months p
KBASDAI 6.9±1.8 3.3±1.9 <0.0001
Fatigue 7.3±1.7 3.9±2.3 <0.0001
Neck, back, hip pain 7.6±2.0 3.5±2.2 <0.0001
Other joint pain 6.0±2.6 3.0±2.3 <0.0001
Overall discomfort 6.6±2.5 3.1±2.1 <0.0001
Morning stiffness intensity 7.5±2.1 3.4±2.3 <0.0001
Morning stiffness duration 6.6±2.8 2.8±2.2 <0.0001
BASFI 7.6±3.5 3.8±2.6 <0.0001
BASMI 5.0±1.8 4.3±1.9 <0.0001
Tragus-to-wall 17.2±5.6 15.7±5.6 0.0393
Lumbar flexion 2.4±1.6 3.1±1.7 0.0015
Cervical rotation 50.9±25.4 52.0±24.5 0.7387
Lumbar side flexion 8.8±7.9 11.8±10.5 0.0171
Intermalleolar distance 95.5±10.4 95.4±10.5 0.9424
HRQoL
SF-36 Physical 28.8±7.5 41.4±24.2 <0.0001
SF-36 Mental 31.3±10.3 44.7±10.4 <0.0001
EQ-5D 0.5±0.2 0.7±0.1 <0.0001
EQ-5D VAS 4.2±2.0 6.3±1.9 <0.0001
CRP (mg/dL) 3.7±3.4 0.4±0.8 <0.0001
ESR (mm/hr) 47±35.3 9±12.0 <0.0001
Table 2. Improvements in outcome measures from baseline
KBASDAI, Korean version of Bath Ankylosing Spondylitis Activity Index;
BASFI, Bath Ankylosing Spondylitis Functional Activity Index; BASMI,
Bath Ankylosing Spondylitis Metrology Index; HRQoL, Health-Related
Quality of Life; SF-36, Short form-36; EQ-5D, EuroQol 5 Dimensions;
VAS, visual analog scale; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate.
Adverse event n (%)
Any adverse event 40 (32.3)
Any serious adverse event 0 (0.0)
Any injection-site reaction 23 (18.5)
Any infection 12 (9.7)
Pruritis 22 (17.7)
URI 9 (7.3)
Fatigue 5 (4.0)
Pharyngitis 3 (2.4)
Rash 1 (0.8)
Headache 1 (0.8)
GI disturbance 1 (0.8)
TB 0 (0)
Table 3. Adverse events
URI, upper respiratory infections; GI, gastrointestinal; TB, tuberculosis.
TB, tuberculosis.
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Fig. 1. Proportion of patients achieving ASAS Criteria.
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olar distance domains failing to reach significance (Table 3).
Health-related quality of life also improved significantly in
both the SF-36 and EQ-5D (p<0.001, for both comparisons)
(Table 2). Improvements were significant in all domains. CRP
and ESR also improved significantly after 3 months (p<0.001,
for both comparisons) (Table 2).
At three months, patients taking NSAIDs decreased from
98.5% to 44.7%, methotrexate from 55.3% to 38.6%, sul-
fasalazine 47.0% to 6.1%, and steroids 29.5% to 6.8%.
Forty (32.3%) patients experienced an adverse event. The
most common treatment-related adverse event was localized
infusion site reaction including pruritis and rash. Upper respi-
ratory infection was the second most common adverse event.
None of the patients developed TB during the study. No seri-
ous adverse events occurred. There were no clinically signif-
icant changes in the values in serum chemistry, hematology
or urine laboratory test, or vital signs.
DISCUSSION
This study was from a prospective cohort of patients who
started on etanercept treatment for treatment of AS at our
hospital. The patients in our cohort were from diverse geo-
graphic location all over Korea and can be representative of
the general Korean AS population. There has been long-term
extended studied of etanercept (23, 24), but the patients
included were from short-term randomized trials with strict
inclusion criteria and cannot represent the general popula-
tion. Therefore, although the study was relatively short in
duration of follow-up, it provides the insight on efficacy and
safety of etanercept in real life until further long-term study
is available. The results were consistent with previous con-
trolled study of etanercept (25-27). Efficacy tended to be
marginally better and adverse events were also not more fre-
quent or severe compared to the controlled trials with con-
fined inclusion criteria. This study showed that etanercept
for treatment of AS was effective in decreasing pain and dis-
ease activity, and also improving physical function and health-
related quality of life. The improvement was apparent in all
domains with the greatest improvement in the morning stiff-
ness intensity followed by neck, back, or hip pain in KBAS-
DAI and the least improvement in intermalloeolar distance
in BASMI. BASMI score as a whole improved significantly,
but the significance was lost when indices were compared
individually, except for lumbar flexion. This was to be expect-
ed since BASMI primarily measures structural damage and
correlates poorly with functional outcome (28). Whether
etanercept can reverse structural damage or not is still under
investigation and even if it does have such an effect it would
not be evident only after three months of therapy. In an anal-
ysis of two randomized controlled trials infliximab (29) and
etanercept (10) for predictive factor for response to treatment
with TNF blocker showed that shorter disease duration,
younger age, lower BASFI score, and higher ESR and CRP
correlated with better responses (30). However, no single
demographic, functional, laboratory, or quality of life factor
correlated with favorable response in our study. TNF block-
ers are effective in improving symptoms, physical function,
mental well-being, quality of life, and may possibly prevent
deforming complications, but once ankylosis develops it is
considered irreversible. So, TNF blockers should be used
without delay in AS patients with inadequate response to
NSAIDs. Unfortunately, even TNF blockers are not univer-
sally effective in all AS patients with less than 80% of the
patient achieving ASAS20 response criteria. Adverse events
also occurs and although there was no serious adverse events
after three months therapy, over 30% of patients experienced
minor adverse events.
Reactivation of TB are of great concern (31) especially in
relative TB endemic areas. Prophylactic treatment of latent
TB has been shown to be effective in preventing active TB
in patients receiving biologic agents (32) and it is recom-
mended by the Korean Center for Diseases Control. Sixteen
(12.1%) patients in this study had a history of TB and 41
(33.1%) were tested positive on TST. However, with TB
prophylaxis there was no incidence of TB. But this was only
a three-month follow-up study and since TB tends to occur
later in the course of treatment with etanercept, further extend-
ed follow-up is needed to be able to draw a conclusion on
TB risk associated with etanercept use in AS.
It has been only ten years since the introduction of etaner-
cept, but anti-TNF agents have revolutionized the treatment
of AS. Preliminary studies have even demonstrated short term
radiographic improvements on magnetic resonance images
with these agents. However, long-term follow-up will be need-
ed to answer long-term effects and adverse events. 
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